To assess the safety and efficacy of Ciclesonide applied as a nasal spray in the treatment of perennial allergic rhinitis (BY9010/M1-402)

Study identifier:BY9010/M1-402

ClinicalTrials.gov identifier:NCT00659750

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray (200 mg once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older

Medical condition

Rhinitis, Allergic, perennial

Phase

Phase 3

Healthy volunteers

No

Study drug

Ciclesonide, Placebo

Sex

All

Actual Enrollment

418

Study type

Interventional

Age

12 Years +

Date

Study Start Date: 01 Dec 2003
Primary Completion Date: 01 May 2004
Study Completion Date: 01 Apr 2005

Study design

Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria